tiziana-logo.png
Tiziana Life Sciences to Host KOL Webinar on Foralumab in Non-Active Secondary Progressive Multiple Sclerosis (SPMS)
25 mai 2023 07h00 HE | Tiziana Life Sciences Ltd.
NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
PharmAla Biotech Logo 800 x 422.png
PharmAla Biotech and Shaman Pharma Granted First Ever Special Access Program Authorization for MDMA
16 mai 2023 11h37 HE | PharmAla Biotech
VANCOUVER, British Columbia, May 16, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA), a biotechnology company focused on the research, development, and manufacturing...
Societal Color Logo and Tagline.png
Societal CDMO to Participate in RBC Capital Markets Global Healthcare Conference
09 mai 2023 16h05 HE | Societal CDMO, Inc.
SAN DIEGO and GAINESVILLE, Ga., May 09, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASD: SCTL), a contract development and manufacturing organization (CDMO)...
NM02 Logo.png
Global Early Toxicity Testing Market to Generate USD 14.39 Billion by 2030, Outlines a New Report by Next Move Strategy Consulting
09 mai 2023 09h00 HE | Next Move Strategy Consulting
New York, May 09, 2023 (GLOBE NEWSWIRE) -- According to a report published by Next Move Strategy Consulting, the Early Toxicity Testing Market generated USD 8.92 billion in 2022, and is projected to...
Societal Color Logo and Tagline.png
Societal CDMO to Report Financial Results for First Quarter 2023 on May 10, 2023
03 mai 2023 16h05 HE | Societal CDMO, Inc.
SAN DIEGO and GAINESVILLE, Ga., May 03, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASD: SCTL), a contract development and manufacturing organization (CDMO)...
PharmAla Biotech Logo 800 x 422.png
PharmAla Biotech to supply Incannex with GMP LaNeo MDMA and Psilocybin
25 avr. 2023 08h00 HE | PharmAla Biotech
VANCOUVER, British Columbia, April 25, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech (MDMA.CSE) is excited to have received a signed purchase order for GMP LaNeo MDMA and Psilocybin by Incannex...
Full Logo - OKYO .jpg
OKYO Pharma Announces Activation of First Clinical Trial Site in the U.S. for the Phase 2 Trial Evaluating OK-101 for the Treatment of Dry Eye Disease
25 avr. 2023 02h00 HE | OKYO Pharma LTD
LONDON and NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO or the “Company”), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101...
EvolveImmune Logo.jpg
EvolveImmune Therapeutics Reports First Results from CRISPR-Cas9 T Cell Exhaustion Screening Platform at American Association for Cancer Research (AACR) Annual Meeting 2023
18 avr. 2023 09h00 HE | EvolveImmune
Novel Technology Identified Genes that Promote T Cell Exhaustion, and which are Unique from PD-1/PD-L1 Checkpoint Pathway Engineered CAR-T Cells Lacking Exhaustion-Associated Genes Mediate Improved...
ihl_logo.png
Incannex Appoints QPS to Advance CannQuit-N™ (Nicotine), CannQuit-O™ (Opioid) and Renecann™ Products in the USA and EU
14 avr. 2023 07h30 HE | Incannex Healthcare
MELBOURNE, Australia, April 14, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (ASX: IHL) (‘Incannex’ or ‘the Company’) a pharmaceutical company developing proprietary medicinal...
PharmAla Biotech Logo 800 x 422.png
PharmAla Biotech and Filament Health Announce Release of GMP MDMA Capsules
11 avr. 2023 08h00 HE | PharmAla Biotech
VANCOUVER, British Columbia, April 11, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”) (CSE:MDMA), a Canadian biotechnology company dedicated to the research and development of...